USE OF ANGIOTENSIN-CONVERTING ENZYME INHIBITORS (ACEIS) AND ANGIOTENSIN-RECEPTOR BLOCKERS (ARBS) AND INCIDENCE OF PNEUMONIA OR INFLUENZA OR COVID-19: A SYSTEMATIC REVIEW AND META-ANALYSIS

WCN23-0291
Special Covid-19
 
 
 
Covid-19 and CKD
 
USE OF ANGIOTENSIN-CONVERTING ENZYME INHIBITORS (ACEIS) AND ANGIOTENSIN-RECEPTOR BLOCKERS (ARBS) AND INCIDENCE OF PNEUMONIA OR INFLUENZA OR COVID-19: A SYSTEMATIC REVIEW AND META-ANALYSIS
Qin, X.(1);Yang, C.(2);Cuixia, X.(1);Zeng, J.(1);Lin, X.(2);Qiu, J.(2);Liu, X.(1);Lu, F.(1);Bao, K.(1);Johnson, D.W.(3);Lundborg, C.S.(4);Nitsch, D.(5);Su, G.(1,4)*;
ie: Azwin Z.1, Siti Y.1, John D.2
(1)Guangdong Provincial Hospital Of Chinese Medicine- The Second Affiliated Hospital Of Guangzhou University Of Chinese Medicine- Guangdong Provincial Academy Of Chinese Medicine Sciences, Department Of Nephrology, Guangzhou, China;(2)Guangzhou University Of Chinese Medicine, Department Of Nephrology, Guangzhou, China;(3)University Of Queensland, Centre For Kidney Disease Research, Brisbane, Australia;(4)Karolinska Institutet, Department Of Global Public Health, Stockholm, Sweden;(5)London School Of Hygiene And Tropical Medicine, Faculty Of Epidemiology And Population Health, London, United Kingdom;
https://storage.unitedwebnetwork.com/files/1041/c3f261ed4c5b20e6c2fe3e5bf7f2ed7f.pdf
 
if any